The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global molecular diagnostics market size reached US$ 17.22 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 27.19 Billion by 2027, exhibiting a growth rate (CAGR) of 7.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use industries. These insights are included in the report as a major market contributor.
Molecular diagnostics refers to a set of laboratory tests that sequences the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or cell proteins of an individual to analyze biomarkers of potential diseases. It assists in diagnosing and monitoring infections and diseases, detecting risks, and assessing therapy response. In recent years, molecular diagnostics has rapidly gained traction in oncology, pharmacogenomics, microbiology, infectious diseases, genetic disease screening, and blood screening. With recent advancements, molecular diagnostics has become an essential aspect of patient-tailored interventions and therapeutics, which is escalating its demand across the globe.
Molecular diagnostics is widely used by hospitals, laboratories, and research institutes for early detection of diseases, coagulation, and human leukocyte antigen typing. As a result, the rising prevalence of chronic conditions, such as cancer, cardiovascular diseases (CVDs), neurological disorders, and infectious diseases, represents the primary factor driving the market growth. Besides this, the growing geriatric population that is more susceptible to developing numerous medical ailments and the widespread adoption of point-of-care (POC) testing devices are catalyzing the product demand. Additionally, the recent outbreak of coronavirus disease (COVID-19) has accelerated the adoption of molecular diagnostic methods, such as polymerase chain reaction (PCR), for COVID-19 testing. Along with this, several favorable initiatives undertaken by the governing agencies and regulatory authorities of various countries, such as fast approvals of diagnostic products to help curb the spread of the virus, are also propelling the market growth. Furthermore, the leading players are making heavy investments to launch innovative diagnostic devices that offer enhanced accuracy, flexibility, cost-effectiveness, and faster results to expand their product portfolio and gain a competitive edge. Other factors, including the escalating demand for personalized treatment, the emerging trend of preventive medicine, improving healthcare infrastructure, and technological advancements, are also creating a positive market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global molecular diagnostics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, technology, application and end users.
Breakup by Product:
Breakup by Technology:
Breakup by Application:
Breakup by End Users:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, Biomerieux SA, Danaher Corporation, Diasorin Molecular LLC (DiaSorin), F. Hoffmann-La Roche AG (Roche Holding AG), Hologic Inc., Illumina Inc., Myriad Genetics Inc., Qiagen, Quidel Corporation and Thermo Fisher Scientific.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Technology, Application, End Users, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, Biomerieux SA, Danaher Corporation, Diasorin Molecular LLC (DiaSorin), F. Hoffmann-La Roche AG (Roche Holding AG), Hologic Inc., Illumina Inc., Myriad Genetics Inc., Qiagen, Quidel Corporation and Thermo Fisher Scientific.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at